Abstract
Objective
To determine the efficacy and safety of intravenous (IV) labetalol in the management of hypertensive crisis in children.
Methods
A retrospective chart review of 56 consecutive children (age > 1 mo to ≤ 12 y) with hypertensive crisis admitted to a pediatric intensive care unit (PICU) from July 2009 to 2019.
Results
The proportion of children attaining the primary endpoint (target 95th percentile in > 12 to ≤ 48 h) was significantly more in the group receiving labetalol as first-line or add-on (n = 23) as compared to those not receiving labetalol (n = 33) (62% vs. 30.3%, p = 0.03). Higher proportion of neurological recovery was seen in the labetalol group (56.2% vs. 18.7%, p = 0.02). The proportion of children with hypotension before 12 h was similar in both treatment groups (13% vs. 15%, p = 0.82). The practice variations between two periods of 5 y each (2009–2013 and 2014–2019) showed significantly more use of labetalol in the latter cohort (53% for 2014–2019 vs. 25% for 2009–2013, p = 0.03).
Conclusion
Labetalol, when used alone or as an add-on drug, was more efficacious than IV nitroprusside/nitroglycerine in attaining the primary endpoint in children up to ≤ 12 y of age with hypertensive crisis. Labetalol was safe and associated with higher neurological recovery.
Similar content being viewed by others
References
Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356(9227):411–7.
Seeman T, Hamdani G, Mitsnefes M. Hypertensive crisis in children and adolescents. Pediatr Nephrol. 2019;34(12):2523–37.
Deal JE, Barratt TM, Dillon MJ. Management of hypertensive emergencies. Arch Dis Child. 1992;67(9):1089–92.
Bunchman TE, Lynch RE, Wood EG. Intravenously administered labetalol for treatment of hypertension in children. J Pediatr. 1992;120(1):140–4.
Thomas CA, Moffett BS, Wagner JL, Mott AR, Feig DI. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med. 2011;12(1):28–32.
Lee GH, Lee IR, Park SJ, Kim JH, Oh JY, Shin JI. Hypertensive crisis in children: an experience in a single tertiary care center in Korea. Clin Hypertens. 2015;22:10.
Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics. 2017;140(3):e20171904.
Chandar J, Zilleruelo G. Hypertensive crisis in children. Pediatr Nephrol. 2012;27(5):741–51.
National High Blood Pressure Education Program Working Group on High Blood Pressure in C, Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. 2004;114(2 Suppl 4th Report):555–76.
Wu HP, Yang WC, Wu YK, Zhao LL, Chen CY, Fu YC. Clinical significance of blood pressure ratios in hypertensive crisis in children. Arch Dis Child. 2012;97(3):200–5.
Gupta-Malhotra M, Banker A, Shete S, et al. Essential hypertension vs. secondary hypertension among children. Am J Hypertens. 2015;28(1):73–80.
Baracco R, Kapur G, Mattoo T, et al. Prediction of primary vs secondary hypertension in children. J Clin Hypertens (Greenwich). 2012;14(5):316–21.
Silverstein DM, Champoux E, Aviles DH, Vehaskari VM. Treatment of primary and secondary hypertension in children. Pediatr Nephrol. 2006;21(6):820–7.
Adelman RD, Coppo R, Dillon MJ. The emergency management of severe hypertension. Pediatr Nephrol. 2000;14(5):422–7.
Author information
Authors and Affiliations
Contributions
MJ, SL, MP conceptualized the study design. SL, MP collected the data. MJ, SL, and MP were involved in the analysis and interpretation of data, and wrote the initial draft, which was critically reviewed and approved by all co-authors. MJ is the guarantor of this paper.
Corresponding author
Ethics declarations
Conflict of Interest
None.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lad, S., Patil, M., Jayashree, M. et al. Efficacy and Safety of Intravenous Labetalol in Acute Hypertensive Crisis in Children. Indian J Pediatr 89, 7–12 (2022). https://doi.org/10.1007/s12098-021-03707-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12098-021-03707-7